Vernalis and Asahi Kasei Pharma Achieve Milestone
Marketwire - Thu Mar 27, 2:01AM CDT
SOURCE: Vernalis PLC
Vernalis Announces Successful Completion of Second Pivotal Bioavailability Study with First Cough Cold Product, CCP-01
M2 - Mon Feb 24, 9:25AM CST
Vernalis Announces Successful Completion of Study
Marketwire - Mon Feb 24, 8:18AM CST
SOURCE: Vernalis PLC
Appointment of Nominated Adviser and Broker
M2 - Mon Feb 10, 4:28AM CST
LSE: VER
Treasury Issues Fresh Rules to Speed Up Public Projects
by Constant Munda - All Africa Global Media - Tue Feb 04, 4:38AM CST
NATIONAL Treasury Secretary Henry Rotich said yesterday that all ministries, departments and state agencies should start the procurement process for their projects before they are allocated funds.
Vernalis Announces Successful Pivotal Single Dose Bioavailability Study with First Cough Cold Product, CCP-01
M2 - Mon Nov 25, 5:36AM CST
LSE: VER
Vernalis Announces Successful Study With CCP-01
Marketwire - Mon Nov 25, 1:10AM CST
SOURCE: Vernalis PLC
Other Central Nervous System Disorders - Pipeline Review, H2 2013
M2 - Tue Nov 19, 3:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/4pwfcw/other_central) has announced the addition of the "Other Central Nervous System Disorders - Pipeline Review, H2 2013" report to their offering. 'Other Central Nervous System Disorders - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Other Central Nervous System Disorders, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Other Central Nervous System Disorders. Scope - A snapshot of the global therapeutic scenario for Other Central Nervous System Disorders. - A review of the Other Central Nervous System Disorders products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Other Central Nervous System Disorders pipeline on the basis of route of administration and molecule type. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Other Central Nervous System Disorders. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Other Central Nervous System Disorders pipeline depth and focus of Indication therapeutics. Key Topics Covered: List of Tables List of Figures Introduction REPORT COVERAGE Other Central Nervous System Disorders Overview Therapeutics Development Companies Involved in Other Central Nervous System Disorders Therapeutics Development Drug Profiles - progesterone - Neuroprotection And Neural Regeneration Program - HF-1220 - mecasermin - rifampin - Oligonucleotide For Rett Syndrome - Protein Fractions Featured News & Press Releases Appendix Companies Mentioned - M et P Pharma AG - Newron Pharmaceuticals S.p.A. - OPKO Health, Inc. - Quark Pharmaceuticals, Inc. - Vernalis plc For more information visit http://www.researchandmarkets.com/research/4p...er_central
Interim results for the six months ended 30 June 2013
M2 - Mon Jul 29, 4:31AM CDT
LSE: VER
Vernalis plc: Interim results for six months ended 30 June 2013
Marketwire - Mon Jul 29, 1:05AM CDT
SOURCE: Vernalis PLC
Nasopharyngitis (Common Cold) - Latest Pipeline Review Report
M2 - Wed Jul 17, 10:00AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zmqdtg/nasopharyngitis) has announced the addition of the "Nasopharyngitis (Common Cold) - Pipeline Review, H1 2013" report to their offering. 'Nasopharyngitis (Common Cold) - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Nasopharyngitis (Common Cold), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Nasopharyngitis (Common Cold). Scope - A snapshot of the global therapeutic scenario for Nasopharyngitis (Common Cold). - A review of the Nasopharyngitis (Common Cold) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stag
Vernalis Initiates Phase Ib/II Proof-of-Concept Study with V81444
M2 - Fri Jul 12, 4:37AM CDT
Vernalis plc today announces that it has dosed the first subjects in a Phase Ib/II proof-of-concept (PoC) study of V81444, an A 2A antagonist which has potential applications for the treatment of Parkinson's disease and other disorders of the central nervous system (CNS).
Vernalis Initiates Phase Ib/II POC Study of V81444
Marketwire - Fri Jul 12, 1:08AM CDT
SOURCE: Vernalis PLC
Notice of Results for the Six Months Ended 30 June 2013
M2 - Thu Jul 11, 5:06AM CDT
LSE: VER
Announcement of Results for the year ended 31 December 2012
M2 - Wed Apr 10, 4:57AM CDT
Vernalis plc (LSE: VER) today announces its audited results for the year ended 31 December 2012.
Vernalis plc: Announcement of Results for year ended 31/12/12
Marketwire - Wed Apr 10, 1:09AM CDT
SOURCE: Vernalis PLC
Notice of Results for the Twelve Months Ended 31 December 2012
M2 - Thu Mar 21, 7:39AM CDT
Vernalis plc today announces its year end results for the twelve months ended 31 December 2012 will be released on Wednesday, 10 April 2013. The earnings announcement will be distributed at 7:00 am (UK) and will be available to download from www.vernalis.com .
First Product in Tris Pharma's Collaboration with Vernalis Achieves Proof-of-Concept, Triggering Milestone Payment to Tris
PR Newswire - Mon Mar 11, 8:00AM CDT
Tris Pharma, a specialty pharmaceutical company focused on developing innovative drug delivery technologies, announced today receipt of a first milestone payment under its U.S. prescription cough/cold collaboration with Vernalis plc (Vernalis). This milestone recognizes the achievement by Tris of proof-of-concept (POC) for the first collaboration compound, CCP-01.
First product in cough cold pipeline achieves proof-of-concept
M2 - Wed Mar 06, 7:09AM CST
LSE: VER
Vernalis and Servier Extend Oncology Collaboration
M2 - Wed Mar 06, 7:08AM CST
LSE: VER